The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 11, 2004, Pages 794-804

  Cheng, Yee Chung ^a   Rondón, Gabriela ^a   Yang, Ying ^a   Smith, Terry L ^a   Gajewski, James L ^a   Donato, Michele L ^a   Shpall, Elizabeth J ^a   Jones, Roy ^a   Hortobagyi, Gabriel N ^a   Champlin, Richard E ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autologous transplantation; Bone marrow; Breast neoplasm; High dose chemotherapy; Neoadjuvant chemotherapy; Peripheral blood progenitor cells

Indexed keywords

ACICLOVIR; ANTHRACYCLINE DERIVATIVE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; ETOPOSIDE; FLT3 LIGAND; FLUCONAZOLE; MESNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; THIOTEPA;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LIVER FAILURE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; NONBIOLOGICAL MODEL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; STEM CELL MOBILIZATION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; THIOTEPA; TRANSPLANTATION, HOMOLOGOUS;

EID: 6444237468     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.07.009     Document Type: Article

References (41)

1. S.E. Jones T.E. Moon G. Bonadonna et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base Am J Clin Oncol. 10 1987 387-395
2. C.L. Carter C. Allen D.E. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181-187
3. M.J. Piccart D. de Valeriola R. Paridaens et al. Six-year results of a multimodality treatment strategy for locally advanced breast cancer Cancer 62 1988 2501-2506
4. N.E. Davidson M.D. Abeloff Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse J Natl Cancer Inst. 84 1992 301-305
5. A.U. Buzdar S.W. Kau G.N. Hortobagyi et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy Cancer 69 1992 448-452
6. G. Bonadonna P. Valagussa A. Moliterni et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med. 332 1995 901-906
7. C.A. Perez M.L. Graham M.E. Taylor et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory Cancer 74 1994 453-465
8. I.A. Jaiyesimi A.U. Buzdar G. Hortobagyi Inflammatory breast cancer: a review J Clin Oncol. 10 1992 1014-1024
9. D.R. McCready G.N. Hortobagyi S.W. Kau et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer Arch Surg. 124 1989 21-25
10. W. Hryniuk H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol. 2 1984 1281-1288
11. W. Hryniuk M.N. Levine Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J Clin Oncol. 4 1986 1162-1170
12. W.M. Hryniuk M.N. Levine L. Levin Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer NCI Monogr. 1 1986 87-94
13. W.P. Peters M. Ross J.J. Vredenburgh et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol. 11 1993 1132-1143
14. E. van der Wall W.J. Nooijen J.W. Baars et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach Br J Cancer 71 1995 857-862
15. H.K. Holland S.P. Dix R.B. Geller et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care J Clin Oncol. 14 1996 1156-1164
16. K.H. Antman P.A. Rowlings W.P. Vaughan et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol. 15 1997 1870-1879
17. A.M. Gianni S. Siena M. Bregni et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results J Clin Oncol. 15 1997 2312-2321
18. S.I. Bearman B.A. Overmoyer B.J. Bolwell et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes Bone Marrow Transplant. 20 1997 931-937
19. J.F. Tomas R. Perez-Carrion A. Escudero et al. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer Bone Marrow Transplant. 19 1997 331-336
20. H.T. Greinix W. Linkesch M. Seifert et al. Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients Acta Oncol. 39 2000 47-52
21. F. Gutierrez-Delgado L.A. Holmberg H. Hooper et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer Bone Marrow Transplant. 26 2000 51-59
22. M.J. Stuart W.P. Peters G. Broadwater et al. High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes Biol Blood Marrow Transplant. 8 2002 666-673
23. S.M. Stemmer I. Hardan H. Raz et al. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients Bone Marrow Transplant. 31 2003 655-661
24. R. Garcia-Carbonero M. Hidalgo L. Paz-Ares et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer J Clin Oncol. 15 1997 3178-3184
25. S. Rodenhuis D.J. Richel E. van der Wall et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 352 1998 515-521
26. G.N. Hortobagyi A.U. Buzdar R.L. Theriault et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma J Natl Cancer Inst. 92 2000 225-233
27. J. Bergh T. Wiklund B. Erikstein et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study Lancet 356 2000 1384-1391
28. J.G. Schrama I.F. Faneyte J.H. Schornagel et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up Ann Oncol. 13 2002 689-698
29. M.S. Tallman R. Gray N.J. Robert et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med. 349 2003 17-26
30. S. Rodenhuis M. Bontenbal L.V. Beex et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med. 349 2003 7-16
31. W.P. Peters G. Rosner J. Vredenburgh et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 Proc Am Soc Clin Oncol. 18 1999 1a (abstr.)
32. Y. Nieto P.J. Cagnoni E.J. Shpall et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant Clin Cancer Res. 5 1999 3425-3431
33. G. Somlo J.H. Doroshow S.J. Forman et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival J Clin Oncol. 15 1997 2882-2893
34. Y. Nieto P.J. Cagnoni S. Nawaz et al. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation J Clin Oncol. 18 2000 2070-2080
35. F. Montemurro G. Rondon N.T. Ueno et al. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy Bone Marrow Transplant. 29 2002 861-866
36. A. Goldhirsch R.D. Gelber G. Yothers et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments J Natl Cancer Inst Monogr. 30 2001 44-51
37. T. Palangie V. Mosseri P. Beuzeboc et al. High dose chemotherapy (HDC) and peripheral blood progenitor cells transplant (PBPC) following chemotherapy including vinorelbine, ifosphamide and cis-platinum, in high risk breast cancer patients with residual tumor and axillary lymph node after primary chemotherapy Proc Am Soc Clin Oncol. 22 2003 86 (abstr.)
38. J. Bou-Khalil M. Rose A. Psyrri et al. Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer Breast J. 9 2003 472-477
39. C. Botti P. Vici M. Lopez et al. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast J Am Coll Surg. 181 1995 202-208
40. R. Wong G. Rondón R.M. Saliba et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer Bone Marrow Transplant. 31 2003 1157-1163
41. W.P. Peters G. Rosner J. Vredenburgh et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13 Proc Am Soc Clin Oncol. 20 2001 21a (abstr.)